Background: Thalassemia is a hematological disorder that is caused by mutations in the genes that encode hemoglobin chains. Mutations in the β-globin gene are the most common cause of genetic disorders in humans, with 350 β-thalassemia variants identified to date. The objective of the study was to evaluate the hematological parameters in pediatric patients with beta thalassemia major. Methods: From January 2021 to November 2021, thirty beta thalassemia major children were recruited from the pediatric hematology outpatient clinic for this cross-sectional study. On the basis of their iron chelation therapy, the patients were divided into two groups: Group I: Deferasirox was administered to fifteen patients as a single iron chelation therapy. Group II: Deferasirox and deferiprone were administered to fifteen patients as part of combined iron chelation therapy, both drugs were given with one another every week for a period of 11 months. Furthermore, our patients were classified to splenectomized and unsplenectomized patients. All studied patients underwent a comprehensive clinical examination, history-taking, and laboratory investigations, including serum ferritin and complete blood count (CBC). Results: patients in group II required significantly more blood transfusions per year than those in group I, p= 0.007 and their disease duration was significantly longer, p < 0.0001. Hemoglobin, white blood cells and serum ferritin did not exhibit any substantial disparities between the studied groups. Splenectomized patients had higher platelet count compared to unsplenectomized counterparts, P= 0.047. Conclusions: Hematological parameters showed no significant differences among the studied groups of beta thalassemia major patients except for significantly higher platelet count in splenectomized patients. The combined treatment with deferasirox and deferiprone in a sequential manner doesn't seem to offer any more advantage compared to single therapy by deferasirox in decreasing serum ferritin between group I and group II. Daily simultaneous regimens of iron chelators could be used in place of sequential use every other week. Antiplatelet treatment is essential for our splenectomized patients.